It doesn't but you are rather missing the importance (as the market did) of the Novartis deal. $1.7 billion in potential payments rather subdues that need. SI is discussing a commercial partnership with several big Pharma's with regard to CHF. The dreaded CR acronym is something that was relegated to the rear view mirror with Novartis and will be a speck on it if another deal announced on these results today....very likely.
I urge people to look at Fate Therapeutics in the US, that got a J&J partnership of slightly larger montetary value. That stem cell company went from less than $2 billion mkt cap on the deal to now $8.5 billion - alas I didn't have anywhere near as much money in it as I do MSB, because I consider MSB's prospects better.
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Heart Failure Results
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-388
-
- There are more pages in this discussion • 635 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
96.0¢ |
Change
0.010(1.05%) |
Mkt cap ! $1.096B |
Open | High | Low | Value | Volume |
94.5¢ | 97.5¢ | 94.0¢ | $2.076M | 2.161M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 162826 | 96.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.0¢ | 28820 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 162826 | 0.960 |
6 | 80489 | 0.955 |
6 | 62777 | 0.950 |
1 | 5500 | 0.945 |
9 | 112571 | 0.940 |
Price($) | Vol. | No. |
---|---|---|
0.970 | 28820 | 3 |
0.975 | 27691 | 4 |
0.980 | 60702 | 4 |
0.985 | 70702 | 3 |
0.990 | 93055 | 5 |
Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |